Problem statement
Anti-Müllerian hormone (AMH) as a tool to predict ovarian responsiveness to controlled ovarian hyperstimulation (COH) has been used currently. Despite a strong positive correlation between serum AMH level and ovarian response to COH, the role of serum AMH as a tool to predict clinical outcomes is a matter of debate. Especially in young women with extremely low serum AMH is more pronounced debate. Therefore, the aim of this study was to compare the IVF outcomes according to age in women with extremely low serum AMH.

Methods
 The outcome of 344 fresh IVF cycles in 199 patients with serum AMH level between 0.1 and 0.2ng/ml was retrospectively analyzed, observed from January 2014 to December 2016 in single infertility center. From the database, cycle cancellation rate, implantation rate (IR), clinical pregnancy rate (CPR), live birth rate (LBR) were compared between the group in three age groups. The first group was from 30 to 34 years old. The age of second group was from 35 to 39. The third group was from 40 to 43 years old.

Results
 There were no significant differences in cycle cancellation rate between three groups (17.3% vs. 15.3% vs. 21.8%, p>0.05). Also, the number of mature oocytes and fertilization rate were no significant differences. Among those who reached oocyte pick up (OPU), age significantly affected the success rate: patients under 40 years had significantly better implantation rate (IR: Group 1 22.2% vs. Group 3 3.5%, Group 2 14.3% vs. Group 3 3.5%, p<0.05), clinical pregnancy rate (CPR: Group1 29.2% vs. Group 3 8.9%, p<0.05), and live birth rate (LBR: Group 1 25.0% vs. Group 3 2.2%, Group 2 13.0% vs. Group 3 2.2%, p<0.05) than patients aged 40-43. 

Conclusion
Under 40 years old had significantly better IR, CPR and LBR than group of over 40 years age. Therefore, patients under 40 years of age with extremely low serum AMH levels may be consider IVF procedure and still have chances of achieving a pregnancy. We also may provide appropriate counseling and information.

26 - PREGNANCY OUTCOMES OF PATIENTS ACCORDING TO AGE WITH EXTREMELY LOW SERUM ANTI-MÜLLERIAN HORMONE IN IVF-ET CYCLES